Most Read Articles
Roshini Claire Anthony, 10 Jul 2019

Women who receive a single dose of amoxicillin and clavulanic acid within 6 hours of operative vaginal delivery could significantly reduce their postpartum infection risk, according to the UK-based ANODE* trial.

17 Jun 2019
Podcast: Dr Sara Hurvitz highlights that the addition of ribociclib to endocrine therapy improved overall survival in premenopausal women with HR+, HER2- advanced breast cancer, according to the MONALEESA-7 trial.
Audrey Abella, 05 Jul 2018
The addition of the sodium-glucose cotransporter-2 inhibitor ertugliflozin to metformin improved glycaemic control, body weight, and blood pressure (BP) in patients with inadequately controlled type 2 diabetes (T2D), according to the results of the VERTIS MET* trial presented at ADA 2018.
17 Feb 2019
In patients with type 2 diabetes (T2D), sodium-glucose cotransporter 2 (SGLT2) inhibitor monotherapy, particularly canagliflozin, exerts greater effects on weight compared with metformin and dipeptidyl peptidase 4 (DPP-4) inhibitors or gliptins, according to the results of a meta-analysis.

Opioids unlikely to be helpful for long-term management of chronic noncancer pain

13 Jun 2019

The use of opioids may have limited long-term efficacy in the management of chronic noncancer pain (CNCP), reports a new study.

Researchers conducted a 2-year prospective cohort study including 529 CNCP patients (71.6 percent female). Propensity score matching was performed to control for characteristic differences between those with and without opioid use. The Brief Pain Inventory and short version of the Treatment Outcomes in Pain Survey were used to assess pain outcomes and quality of life.

At baseline, the prevalence of opioid prescription was 59.7 percent. Of the 316 prescriptions, 86 (16.2 percent) were for strong opioids. The overall rate rose to 60.3 percent (n=319) and 72.6 percent (n=384) after 5 and 12 months of follow-up. While there was a slight dip in overall prescription prevalence by 24 months (70.3 percent; n=372), prescription prevalence for strong opioids grew substantially (42.7 percent; n=226).

After propensity score matching, researchers found no clear indication that long-term opioid use held significant benefits. At 12 months, in nonusers, for example, the rates of clinical improvement in pain symptoms (p=0.014), physical function of the lower body (p=0.014) and severity (p=0.001) were significantly higher than their opioid-using counterparts.

In contrast, users showed a significantly higher rate of improvement in satisfaction with outcomes (p=0.030) and with care (p=0.044).

“Opioid users presented no improvement regarding pain relief, functional outcomes and quality of life over 2 years of follow-up. Therefore, our results support and highlight the limited effectiveness of opioids in long-term CNCP management,” said researchers.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Roshini Claire Anthony, 10 Jul 2019

Women who receive a single dose of amoxicillin and clavulanic acid within 6 hours of operative vaginal delivery could significantly reduce their postpartum infection risk, according to the UK-based ANODE* trial.

17 Jun 2019
Podcast: Dr Sara Hurvitz highlights that the addition of ribociclib to endocrine therapy improved overall survival in premenopausal women with HR+, HER2- advanced breast cancer, according to the MONALEESA-7 trial.
Audrey Abella, 05 Jul 2018
The addition of the sodium-glucose cotransporter-2 inhibitor ertugliflozin to metformin improved glycaemic control, body weight, and blood pressure (BP) in patients with inadequately controlled type 2 diabetes (T2D), according to the results of the VERTIS MET* trial presented at ADA 2018.
17 Feb 2019
In patients with type 2 diabetes (T2D), sodium-glucose cotransporter 2 (SGLT2) inhibitor monotherapy, particularly canagliflozin, exerts greater effects on weight compared with metformin and dipeptidyl peptidase 4 (DPP-4) inhibitors or gliptins, according to the results of a meta-analysis.